3.30Open4.17Pre Close1 Volume622 Open Interest240.00Strike Price330.00Turnover6506.63%IV3.56%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry3.30Extrinsic Value100Contract SizeAmericanOptions Type-0.3385Delta0.0257Gamma74.38Leverage Ratio-9187.4262Theta0.0000Rho-25.18Eff Leverage0.0008Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet